Media Coverage
Media Coverage
BioPharma Dive’s report, leveraging DealForma’s data, uncovers a steep decline in investment for cell and gene therapy developers, attributed to manufacturing and drug delivery challenges, as investors increasingly favor biotechnology companies with more defined development paths. Check out Biopharma Dive’s report.
Stifel’s report, utilizing DealForma’s data, outlines the recent market turbulence, focusing on the sharp declines in tech and biotech stocks due to changes in Japanese interest rates and the resulting impact on investors, while also addressing the potential effects of upcoming political events on the biotech sector. Explore Stifel’s research.
The WSJ article, using data from DealForma, discusses how major pharmaceutical companies have scaled down their acquisition strategies in 2024, focusing on smaller targets priced at $5 billion or less, primarily due to tighter regulatory scrutiny and a smaller pool of large-scale acquisition targets. Check out WSJ’s article.
Nature’s report explores the current state of biotech financing, detailing robust mergers and acquisitions activity and significant private funding rounds, contrasted with difficult public markets and selective venture capital investments, using data from DealForma. Check out Nature’s research.
Stifel’s Mid-2024 Halftime Report, packed with DealForma data, on the biotech market highlights the mixed investor sentiment, strong mid-sized M&A activity, improving inflation, and a predicted robust but bumpy market recovery for the rest of the year. Explore Stifel’s research.
Stifel’s latest update, partly using DealForma data, reviews recent data and updates on the rapidly advancing obesity pharmaceutical market, including insights from the American Diabetes Association and upcoming EASD abstracts. Explore Stifel’s research.
Stifel’s latest update, using DealForma data, reports key oncology pharma market trends, including substantial ASCO conference activity, game-changing therapies, and rising cancer drug spending. Explore the full oncology update.
Stifel’s latest update, using DealForma data, reports key biopharma market events. Highlights include hawkish Fed impacts on biotech stocks, Biogen’s $1.15B HI-Bio acquisition, and $1.7B in follow-on offerings. Checkout the Stifel story.
David H. Crean highlights robust activity in life sciences for Q1 2024, featuring key M&As, IPOs, and venture funding, despite economic challenges, as detailed by DealForma data. Read the full report
Venture investment in biopharma and medtech has remained strong through the first quarter of 2024, as detailed in J.P. Morgan’s latest report, which utilizes data compiled by DealForma. Download the reports
Stifel’s recent report, leveraging data from the DealForma database, highlights key trends in biopharma M&A, including a rise in high-value deals and significant activity in immunology and oncology sectors. Checkout the Stifel story
Artificial intelligence and machine learning are changing the pharmaceutical sector, affecting drug discovery, clinical trials, and other areas, according to a report by Stifel that used Dealforma’s data. Checkout the Stifel story